- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | Cantor Fitzgerald initiates CAMP4 Therapeutics stock with Overweight rating | 1 | Investing.com | ||
| 02.10. | Cantor Fitzgerald startet Coverage für CAMP4 Therapeutics mit "Overweight" | 3 | Investing.com Deutsch | ||
| 01.10. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy | 1 | Investing.com | ||
| 01.10. | CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 | 93 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory... ► Artikel lesen | |
| 16.09. | JPMorgan downgrades CAMP4 Therapeutics stock to Neutral on long timeline | 1 | Investing.com | ||
| 15.09. | CAMP4 Therapeutics stock price target lowered to $12 at Piper Sandler | 1 | Investing.com | ||
| CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.09. | Piper Sandler senkt Kursziel für CAMP4 Therapeutics auf 12 US-Dollar | 1 | Investing.com Deutsch | ||
| 10.09. | CAMP4 Therapeutics stock soars after $100 million private placement | 4 | Investing.com | ||
| 10.09. | CAMP4 Therapeutics: CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders | 4 | GlobeNewswire (USA) | ||
| 10.09. | Camp4 Therapeutics Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 15.08. | Camp4 Therapeutics GAAP EPS of -$0.62 beats by $0.06, revenue of $1.5M beats by $1.2M | 1 | Seeking Alpha | ||
| 13.06. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | Wedbush bewertet CAMP4-Aktie mit "Outperform" und setzt Kursziel bei 8 US-Dollar | 1 | Investing.com Deutsch | ||
| 16.05. | CAMP4 Therapeutics: CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders ... | 1 | GlobeNewswire (USA) | ||
| 13.05. | Camp4 Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | CAMP4 Therapeutics: CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights | 247 | GlobeNewswire (Europe) | Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected... ► Artikel lesen | |
| 02.05. | Pre-market Movers: Classover Holdings, Block, Inc., Advantage Solutions, Ardelyx, CAMP4 Therapeutics | 992 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Classover Holdings, Inc. (KIDZ) is up over 65% at... ► Artikel lesen | |
| 28.04. | CAMP4 Therapeutics: CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,270 | +0,49 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 48,550 | +3,61 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| ARCELLX | 84,07 | +0,85 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 6,590 | 0,00 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,250 | +0,53 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 57,76 | +3,53 % | Mizuho startet Coverage für Kymera Therapeutics mit "Outperform" | ||
| HARMONY BIOSCIENCES | 29,600 | +12,68 % | Harmony Biosciences Rises 10.6% On Strong Q3 WAKIX Results And Upgraded Guidance | ||
| NUVALENT | 90,89 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| TANGO THERAPEUTICS | 7,510 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces $225 Million Financing | BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| NURIX THERAPEUTICS | 10,400 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,720 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| 89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| EVOTEC | 6,866 | +2,08 % | Evotec Aktie: Gefährlich! Breakversuch scheint erneut zu scheitern | Wieder läuft die Evotec Aktie auf massive charttechnische Hindernisse an der 7-Euro-Marke an - und wieder könnte sie scheitern. Im Handel am Donnerstag erreichte die Biotech-Aktie auf XETRA in der Spitze... ► Artikel lesen | |
| COGENT BIOSCIENCES | 14,840 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
| MAZE THERAPEUTICS | 29,900 | +2,54 % | Maze Therapeutics files to sell 9.23M shares of common stock for holders |
Das Unternehmen CAMP4 THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,300 (+9,43 %) liegt der Kurs bei 3,480 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.